iosBio receives UK grant to develop oral vaccine against Nipah virus
23. Februar 2022 02:00 ET
|
iosBio
PRESS RELEASE iosBio receives UK grant to develop oral vaccine against Nipah virus Zoonotic virus often cited as future pandemic threat and requiring urgent R&D actioniosBio’s oral vaccine...
iosBio appoints Patricia Londono-Hayes as Chief Development Officer
14. Juni 2021 02:00 ET
|
iosBio
PRESS RELEASE iosBio appoints Patricia Londono-Hayes as Chief Development Officer Oral vaccines and biotherapeutics company strengthens senior leadership team with new role to drive priority...
iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19
12. Januar 2021 07:00 ET
|
iosBio
PRESS RELEASE iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19 iosBio licenses its OraProTM...
iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19
12. Januar 2021 02:00 ET
|
iosBio
PRESS RELEASE iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19 iosBio licenses its OraProTM...
Stabilitech Biopharma announces name change to iosBio
30. September 2020 02:00 ET
|
iosBio
PRESS RELEASE Stabilitech Biopharma announces name change to iosBio Burgess Hill, UK, 30 September 2020, STABILITECH BIOPHARMA (the “Company”), a UK-based biotechnology company developing next...